Eiger BioPharmaceuticals announced that David Cory has resigned as President, CEO and member of the Board of Directors, effective immediately.David Apelian, Senior Clinical Advisor and member of the Board of Directors, has been named as interim CEO and will also continue to serve on the company’s Board of Directors. The company plans to initiate an executive search to identify candidates to serve as a permanent CEO. Apelian has 23 years of clinical development and regulatory experience with large pharmaceutical and biotechnology companies, including nearly six years in senior management, advisory and Board roles at Eiger. He has been serving as a Director since 2017 and in 2018 was appointed COO and Executive Medical Officer.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EIGR:
- Biotech Alert: Searches spiking for these stocks today
- Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG
- Eiger BioPharmaceuticals price target lowered to $3 from $29 at Baird
- Eiger BioPharmaceuticals price target lowered to $4 from $23 at Citi
- Eiger Biopharmaceuticals Plunges 70% on New Phase 3 Data